Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Abraxis BioScience Inc.
20 7월 2010 - 5:16AM
Business Wire
Bull & Lifshitz, LLP announces an investigation into
possible breaches of fiduciary duty in connection with the proposed
acquisition of Abraxis BioScience Inc. (NASDAQ: ABII - News)
(referred to as "Abraxis BioScience" or the “Company”) by Celgene
Corporation (NASDAQ: CELG - News) (referred to as “Celgene”).
Under the terms of the merger agreement, each share of Abraxis
BioScience common stock will be converted into the right to receive
an upfront payment of $58.00 in cash and 0.2617 shares of Celgene
common stock. The upfront payment values Abraxis BioScience at
approximately $2.9 billion, net of cash. Each share will also
receive one tradeable Contingent Value Right (CVR), which entitles
its holder to receive payments for future regulatory milestones and
commercial royalties.
Bull & Lifshitz, LLP's investigation is focused on whether
the proposed deal provides adequate value to the Company’s
shareholders.
If you are a holder of Abraxis BioScience stock and want to
discuss your legal rights, you may e-mail or call Bull &
Lifshitz, LLP who will, without obligation or cost to you, attempt
to answer your questions.
If you are a shareholder of Abraxis BioScience and would like
more information about our investigation, please contact Joshua M.
Lifshitz, Esq. by telephone at (866) 313-6222 or by sending an
e-mail including your contact information to:
counsel@nyclasslaw.com. All e-mail correspondence should make
reference to Abraxis BioScience.
Bull & Lifshitz, LLP is a New York City-based law firm with
significant experience representing investors in merger-related
shareholder class actions, shareholder derivative actions, and
securities fraud class actions. For more information about the
firm, please visit our website at www.nyclasslaw.com.
ATTORNEY ADVERTISING. © 2010 Bull & Lifshitz, LLP.
The law firm responsible for this advertisement is Bull &
Lifshitz, LLP, 18 East 41st Street, New York, New York 10017, (212)
213-6222. Prior results do not guarantee or predict a similar
outcome with respect to any future matter.
Abraxis Bioscience Inc. (MM) (NASDAQ:ABII)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Abraxis Bioscience Inc. (MM) (NASDAQ:ABII)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Abraxis Bioscience Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Bull & Lifshitz, LLP News Articles